Aktis Oncology Inc · Q1 2026 earnings

Briefing

Aktis Oncology Inc Q1 fiscal 2026: $3.23B revenue, $18.3M net loss

for the year ended December 31, 2025 which was filed with the Securities and Exchange Commission ("SEC") on March 30, 2026. (SEC accession 0001193125-26-216749)

• Revenue: $3.23B
• Net loss: $18.3M
• Diluted EPS: $-0.38
• Operating income: $-22.7M

Headline financials

Revenue & EPS history